|
The City of Frederick is the hub of arts, culture, commerce and government within Frederick County. Located less than an hour from Washington, D.C. and Baltimore, MD, Frederick is the second largest city in Maryland with 65,000 residents. Frederick offers a balanced and thriving economy, a highly educated workforce, and a quality of life that is nothing short of enviable. |
|
ROCKVILLE AND BALTIMORE, MARYLAND, January 6, 2014 – BioHealth Innovation, Inc. (BHI) and MIMETAS announced today that Todd Chappell, MBA, an Entrepreneur-in-Residence for BHI, has been named General Manager, U.S. Affairs for MIMETAS. A Netherlands-based company, MIMETAS is establishing its offices within BHI’s headquarters in Rockville. MIMETAS and BHI created a U.S. subsidiary of MIMETAS to access the clinical, regulatory and scientific resources available in Central Maryland and to access the U.S. marketplace, the largest life sciences market in the world.
“We’re very pleased to add Todd to the MIMETAS team,” said Jos Joore, Ph.D., Chief Business Officer of MIMETAS. “Todd couples a vast experience in business creation with a profound understanding of biology and disease mechanisms. Most importantly, Todd shares our sense of urgency around enabling better medical treatment by using more predictive cell culture models.”
Previously, Mr. Chappell was the Vice President of Operations for Shape Pharmaceuticals, a portfolio company of HealthCare Ventures, LLC, where he oversaw all day-to-day operations involved in the development of a novel HDAC inhibitor for Cutaneous-T-Cell-Lymphoma. Prior to that, he was at CombinatoRx Inc. for eight years and served as Director of New Products. Mr. Chappell will be combining his role at MIMETAS with his existing EIR position at BHI.
MIMETAS and BHI created a U.S. subsidiary of MIMETAS to access the clinical, regulatory and scientific resources available in Central Maryland and to access the U.S. marketplace, the largest life sciences market in the world.
“We’re very pleased to add Todd to the MIMETAS team,” said Jos Joore, Ph.D., Chief Business Officer of MIMETAS. “Todd couples a vast experience in business creation with a profound understanding of biology and disease mechanisms. Most importantly, Todd shares our sense of urgency around enabling better medical treatment by using more predictive cell culture models.”
On Tuesday, January 7th from 4-7 pm there will be an open house for the spring courses in the “Advanced Studies in Technology Transfer” certificate program at the FAES Graduate School at NIH in the new FAES Classroom & Bookstore complex in Building 10 / B1 level. For the semester beginning on January 27th there will be 10 courses available with enrollment open to the general community:
More details can be found in the spring 2014 course catalog supplement (www.faes.org). Course credit is transferable as well into various MBA & MS degree programs at the University of Maryland University College (UMUC) Graduate School as well as the new Master of Biotechnology Enterprise and Entrepreneurship degree program at Johns Hopkins University.
Defense and government contracting giant Northrop Grumman is making a bet on young start-ups by supporting a business accelerator for healthcare-related ventures.
The Falls Church-based company partnered with Johns Hopkins University, Rockville-based nonprofit BioHealth Innovation, which helps bioscience research projects in Maryland find funding, and Philadelphia venture capital firm DreamIt Ventures to start the new accelerator, to be based in Baltimore. DreamIt has operated similar programs for start-ups across other industries in several cities nationwide.
The goals of this initiative are to: 1) develop strategies and methodologies for the sequencing, mapping and genomic analyzing of established phenotypes of selectively bred animal models with addiction traits, and 2) identify, from new or existing selectively bred animal models, genetic variants with implications for addiction related traits.
